期刊文献+

GnRHa联合低剂量hCG扳机在高反应多囊卵巢综合征患者体外受精中的应用 被引量:16

GnRHa combined with low dose hCG trigger in in vitro fertilization treatment of polycystic ovary syndrome high responders
原文传递
导出
摘要 目的探讨多囊卵巢综合征(PCOS)高反应患者行体外受精/卵胞质内单精子显微注射(IVF/ICSI)治疗使用低剂量联合扳机的安全性和有效性。方法回顾性队列分析2014年1月1日—2015年12月31日期间在本院生殖医学中心采取促性腺激素释放激素拮抗剂(GnRH-A)方案进行控制性促排卵行IVF/ICSI助孕的PCOS患者(n=364)的临床资料,分为低剂量联合扳机组(GnRH-A+低剂量hCG,A组,n=127)和标准扳机组(hCG,B组,n=237)。分析比较因卵巢高反应采用不同扳机方案患者的临床资料。结果患者一般情况和促排卵治疗用药组间均无统计学差异(P>0.05)。A组患者hCG扳机日血清E_2水平[(19193.9±7837.5)pmol/L]及获卵数(29±9)均显著高于B组患者[(15786.8±7104.1)pmol/L,P<0.05;24±6,P<0.05]。两组患者的ICSI授精率、M_Ⅱ卵比率及双原核(2PN)胚胎率均无统计学差异(P>0.05)。A组患者冻存胚胎数(14±6)显著多于B组患者(12±5,P<0.05)。中重度卵巢过度刺激综合征(OHSS)发生率无统计学差异(P>0.05)。冻融移植周期A组患者胚胎复苏率(62.3%)显著低于B组(77.0%,P<0.05)。两组患者的移植胚胎数、临床妊娠率、着床率、流产率及活产率均无统计学差异(P>0.05)。结论对于高反应PCOS患者使用拮抗剂方案基础上,应用减量联合扳机并全部胚胎冻存,不增加重度OHSS发生率,冻融胚胎移植周期也得到了满意的治疗结局。 Objective To investigate the effectiveness and safety of low dose human chorionic gonadotropin(hCG) dual trigger in polycystic ovary syndrome(PCOS) high-responders who underwent in vitro fertilization/intracytoplasmic sperm injection(IVF/ICSI). Methods This was a retrospective cohort study. There were 364 infertile patients with PCOS high-responders accepted IVF/ICSI treatment in Reproductive Medical Center of Peking University, between Jan. 1st 2014 and Dec. 31st 2015, with GnRH antagonist flexible protocol. The patients were divided into two groups depending on different trigger protocols. Group A was low dose hCG dual trigger group(n=127), while group B was standard trigger group(n=237). The general characteristics and treatment outcomes were compared between two groups. Results There were no significant differences between the two groups refer to general characteristics, and Gn used dosage(P〉0.05). The serum E2 level on hCG trigger day [(19193.9 ±7837.5) pmol/L]and mean number of oocyte retrieved(29 ± 9) in group A were significantly higher than those in group B [(15786.8 ±7104.1) pmol/L,P〈0.05; 24 ±6, P〈0.05]. The ICSI rate, MⅡ oocyte rate and 2 pronuclear(2 PN) embryo rate were comparable of two groups(P〉0.05).The number of frozen embryos were significantly higher in group A(14 ± 6) than that in group B(12 ±5, P〈0.05). The severe ovarian hyperstimulation syndrome(OHSS) rate was comparable in two groups(P〉0.05). In frozen-thawed cycles, the embryo survival rate was significantly lower in group A(62.3%) than in group B(77.0%, P〈0.05). The number of transferred embryos, clinical pregnancy rate, implantation rate, miscarriage rate and live birth rate were comparable in the two groups(P〉0.05). Conclusion For high responders of PCOS patients, besides of GnRH antagonist protocol, using low dose hCG dual trigger and freeze all protocol, will not increase the incidence of OHSS. Furthermore, the frozen-thawed cycles will get satisfied treatment outcomes.
出处 《中华生殖与避孕杂志》 CAS CSCD 北大核心 2017年第12期958-962,共5页 Chinese Journal of Reproduction and Contraception
关键词 多囊卵巢综合征(PCOS) 促性腺激素释放激素拮抗剂(GnRH-A) 控制性卵巢刺激(COS) 促性腺激素释放激素激动剂(GnRHa)扳机 联合扳机 Polycystic ovary syndrome (PCOS) GnRH antagomst Controlled ovarian stimulation (COS) CatRH agomst trigger Dual trigger
  • 相关文献

参考文献2

二级参考文献75

  • 1Papanikolaou EG, Pozzobon C, Kolibianakis EM, et al. Incidence and prediction of ovarian hyperstimulation syn- drome in women undergoing gonadoWopin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril, 2006, 85 (1):112-20.
  • 2Busso C, M, Garcia-Velasoa JA, etal. The non-ergot derived dopamine agonist quinagolide in pre- vention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-ennm)lled trial. Hum Reprod, 2010, 25(4):995-1004.
  • 3Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril, 2010, 94(2):389-400.
  • 4Al-Inany HG, Youssef MA, Aboulghar M, et al. Gonadotro- phin-releasing hormone antagonists for assisted reproduc- tive technology. Cochrane Database Syst Rev, 2011(5): CD001750.
  • 5Fiedler K, Ezcurra D. Predicting and preventing ovarian hyperslsulafion syndrome (OHSS): the need for individualized not standardized treatment. Reprod Biol Endoerinol, 2012, 10:32.
  • 6Tsoumpou I, Muglu J, G-elbaya TA, et al. Symposium: Update on prediction and management of OHSS. Optimal dose of HCG for final ooeyte maturation in IVF cycles: absence of evidence? Reprod Biomed Online, 2009, 19(1):52-8.
  • 7Lainas TG, Sfontouris IA, Zorzovilis IZ, et al. Management of severe early ovarian hyperstimulation syndrome by re- initiation of CmRH antagonist. Reprod Biomed Online, 2007, 15(4):408-12.
  • 8Lainas TG, Sfontouris IA, Zorzovilis IZ, et al. Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol. Reprod Biomed Online, 2009, 18( 1): 15-20.
  • 9Wada I, Matson PL, Home G, et al. Is continuation of a gouadotrophin-releasing hormone agonist (CmRHa) necessary for women at risk of developing the ovarian hyper-stimulation syndrome? Hum Reprod, 1992, 7(8): 1090-3.
  • 10Endo T, Hounma H, Hayashi T, et al. Continuation of GnRH agonist administration for 1 week, after hCG injection, pre- vents ovarian hyperstimtdation syndrome following elective cryopreservation ofaU pronucleate embryos. Hum Reprod, 2002, 17(10):2548-51.

共引文献93

同被引文献90

引证文献16

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部